Medicare Enrolled
Dr. Ronjay Rakkhit, M.D.
Internal Medicine · Houston, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Rakkhit from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rakkhit?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rakkhit
Dr. Ronjay Rakkhit is an internal medicine specialist in Houston, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Rakkhit performed 178,592 Medicare services across 2,244 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rakkhit received a total of $13,481 from 75 pharmaceutical and/or device companies across 586 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rakkhit is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 0% volume in TX
$13,481 industry payments
Medicare Practice Summary
Medicare Utilization ↗178,592
Medicare services
Top 0% in TX for internal medicine
2,244
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~9,400 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 77,520 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia | 47,200 | $2 | $13 |
| Pembrolizumab injection (Keytruda) | 24,600 | $43 | $223 |
| Contrast dye for imaging (iodine-based) | 10,600 | $0 | $0 |
| Anti-nausea injection (fosaprepitant) | 7,500 | $0 | $1 |
| Dexamethasone injection (steroid) | 2,090 | $0 | $1 |
| Epoetin alfa injection (Procrit) for anemia | 1,800 | $6 | $33 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,510 | $1 | $4 |
| Complete blood count (CBC) with differential | 1,192 | $8 | $24 |
| Office visit, established patient (20-29 min) | 820 | $65 | $278 |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 516 | $97 | $553 |
| Blood draw (venipuncture) | 304 | $8 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 297 | $22 | $91 |
| Drug injection, under skin or into muscle | 291 | $11 | $53 |
| Administration of chemotherapy into vein, 1 hour or less | 286 | $102 | $417 |
| Injection, carboplatin, 50 mg | 273 | $2 | $11 |
| Injection of additional new drug or substance into vein | 180 | $12 | $49 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 175 | $49 | $203 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 112 | $16 | $71 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 112 | $101 | $492 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 111 | $1,186 | $5,521 |
| Administration of additional new drug or substance into vein, 1 hour or less | 108 | $51 | $205 |
| Administration of chemotherapy into vein, each additional hour | 106 | $20 | $89 |
| New patient office visit (30-44 min) | 99 | $80 | $344 |
| Administration of additional new drug or substance into vein using push technique | 89 | $44 | $175 |
| Blood creatinine level | 82 | $5 | $16 |
| Office visit, established patient (30-39 min) | 78 | $100 | $408 |
| Ct scan of chest before and after contrast | 71 | $58 | $638 |
| Ct scan of abdomen and pelvis before and after contrast | 69 | $212 | $1,119 |
| Irrigation of implanted venous access drug delivery device | 48 | $20 | $81 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 39 | $115 | $496 |
| Injection, diphenhydramine hcl, up to 50 mg | 39 | $1 | $5 |
| Urinalysis, manual | 37 | $3 | $11 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 35 | $16 | $63 |
| CT scan of abdomen and pelvis with contrast | 29 | $176 | $1,019 |
| Blood test, basic group of blood chemicals (calcium, ionized) | 29 | $13 | $43 |
| Ct scan of chest with contrast | 28 | $51 | $570 |
| Infusion into a vein for hydration, 31-60 minutes | 21 | $26 | $104 |
| Office visit, established patient (10-19 min) | 18 | $34 | $177 |
| CT scan of chest, without contrast | 16 | $59 | $430 |
| Echocardiogram, transthoracic | 16 | $108 | $621 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 16 | $1 | $5 |
| New patient office visit, complex (60-74 min) | 15 | $178 | $681 |
| Initial hospital admission, high complexity | 15 | $139 | $567 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
43.7% high complexity
54.5% medium
1.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$13,481
Total received (2018-2024)
Avg $1,926/year across 7 years
Top 7% in TX for internal medicine
75
Companies
586
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,858 (80.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,240 (16.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$383 (2.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,555
2023
$1,912
2022
$3,597
2021
$872
2020
$1,131
2019
$2,271
2018
$2,144
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
SERVIER PHARMACEUTICALS LLC
$2,240
PFIZER INC.
$1,214
Novartis Pharmaceuticals Corporation
$1,181
Janssen Biotech, Inc.
$1,000
E.R. Squibb & Sons, L.L.C.
$859
Amgen Inc.
$805
Celgene Corporation
$583
GENZYME CORPORATION
$429
Genentech USA, Inc.
$411
Janssen Pharmaceuticals, Inc
$335
Gilead Sciences, Inc.
$297
Merck Sharp & Dohme LLC
$267
Astellas Pharma US Inc
$219
Exelixis Inc.
$176
AstraZeneca Pharmaceuticals LP
$161
ARRAY BIOPHARMA INC
$160
Takeda Pharmaceuticals U.S.A., Inc.
$154
Tempus AI, Inc
$154
Medtronic, Inc.
$152
SpringWorks Therapeutics, Inc.
$135
Myriad Genetic Laboratories, Inc.
$124
BeiGene USA, Inc.
$120
GlaxoSmithKline, LLC.
$116
Sirtex Medical Inc
$108
Merck Sharp & Dohme Corporation
$102
Alexion Pharmaceuticals, Inc.
$99
Lilly USA, LLC
$95
Eisai Inc.
$89
Lexicon Pharmaceuticals, Inc.
$86
JAZZ PHARMACEUTICALS INC.
$82
Verity Pharmaceuticals Inc.
$79
Secura Bio, Inc.
$73
Pharmacyclics LLC, An AbbVie Company
$72
Kite Pharma, Inc.
$62
Clovis Oncology, Inc.
$62
Foundation Medicine, Inc.
$61
Boston Scientific Corporation
$59
Jazz Pharmaceuticals Inc.
$58
Puma Biotechnology, Inc.
$56
Incyte Corporation
$54
Bayer HealthCare Pharmaceuticals Inc.
$51
Taiho Oncology, Inc.
$51
Regeneron Healthcare Solutions, Inc.
$45
MorphoSys, US Inc.
$41
PharmaEssentia USA Corporation
$40
Biocompatibles, Inc.
$39
PUMA BIOTECHNOLOGY, INC.
$38
Sobi, Inc
$33
EISAI INC.
$32
Teva Pharmaceuticals USA, Inc.
$32
Fennec Pharmaceuticals, Inc.
$31
TESARO, Inc.
$30
SECURA BIO, INC.
$30
Boehringer Ingelheim Pharmaceuticals, Inc.
$28
Adaptive Biotechnologies Corporation
$24
Apellis Pharmaceuticals, Inc.
$23
AVEO Pharmaceuticals, Inc.
$22
ABBVIE INC.
$22
AbbVie, Inc.
$22
EUSA Pharma (US) LLC
$20
Janssen Scientific Affairs, LLC
$20
Servier Pharmaceuticals LLC
$20
Ipsen Biopharmaceuticals, Inc
$19
Sysmex Inostics Inc
$18
R-Pharm US LLC
$18
Dendreon Pharmaceuticals LLC
$18
EMD Serono, Inc.
$17
INSYS Therapeutics Inc
$16
Spectrum Pharmaceuticals Inc.
$15
Verastem, Inc.
$15
Innate Pharma, Inc
$15
Blueprint Medicines Corporation
$13
Seattle Genetics, Inc.
$12
Acrotech Biopharma LLC
$12
Emmaus Medical, Inc.
$8
Top 3 companies account for 34.4% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · AYVAKIT · Abraxane · Alecensa · BELEODAQ · BENDEKA · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · CABLIVI · CABOMETYX · CHANTIX · COPIKTRA · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · DOPTELET · ELIQUIS · ENHERTU · ENJAYMO · ERLEADA · Empaveli · Endari · Erleada · FARYDAK · FOTIVDA · FOUNDATIONONE · Fabhalta · Farydak · Folotyn · GILOTRIF · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · Ixempra · JADENU · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LORBRENA · LUMAKRAS · Lenvima · Lonsurf · Lumoxiti · MEKINIST · MONJUVI · MYLOTARG · MYRISK · NERLYNX · NINLARO · Neulasta · Nexavar · Nplate · OGSIVEO · OPDIVO · OPDUALAG · OSTEOCOOL RF ABLATION SYSTEM · OXBRYTA · PADCEV · PIQRAY · PROMACTA · PROVENGE · Padcev · Pedmark · Polivy · Pomalyst · Prolia · REBLOZYL · RYDAPT · Rubraca · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNDROS · Stivarga · Sylvant · TASIGNA · TECENTRIQ · THERASPHERE-BIO · TIBSOVO · Tecentriq · TheraSphere Y90 Glass Microspheres 10 GBq · Trelstar · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VOTRIENT · Vectibix · Venclexta · XALKORI · XARELTO · XOSPATA · XT CDX · XTANDI · Xermelo · Xospata · ZEJULA · ZEPZELCA · ZYTIGA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (80%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 7% for internal medicine in TX.
Equivalent to $8 per 100 Medicare services performed
Geographic Context
Internal medicine physicians within 10 mi
2,638
Per 100K population
55.4
County median income
$73,104
Nearest hospital
MEMORIAL HERMANN MEMORIAL CITY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Rakkhit is a mixed practice specialist, with above-average Medicare volume (top 0% in TX), with low-engagement industry engagement in the top 7% of TX peers, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Rakkhit experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Rakkhit performed 77,520 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rakkhit receive payments from pharmaceutical companies?
Yes. Dr. Rakkhit received a total of $13,481 from 75 companies across 586 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rakkhit's costs compare to other internal medicine physicians in Houston?
Dr. Rakkhit's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rakkhit) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Houston
Browse internal medicine physicians in Houston ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in TX
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in TX
Which TX internal medicine physicians receive the most from drug and device companies.
By company
SERVIER PHARMACEUTICALS LLC Payments to Doctors
See all physicians who received payments from SERVIER PHARMACEUTICALS LLC.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology